Gilead's Filing Plans For Magrolimab Depend On Further Data

Company Presents Encouraging Phase Ib Data In TP53-Mutant AML At ASH

 
• By Alaric DeArment

Regardless of future filing based on Phase Ib data, Gilead plugs along with development in TP53-mutant AML, MDS and other cancers.

Leukemia
Gilead presents magrolimab data in acute myeloid leukemia at ASH. • Source: Shutterstock

More from Clinical Trials

More from R&D